Can a radioactive 'Smart Bomb' shrink resistant prostate tumors?

NCT ID NCT06441994

Ongoing Disease control Sponsor: Osaka University Source: ClinicalTrials.gov ↗

First seen Jul 28, 2026 · Last updated Jul 29, 2026 · Updated 1 time

Summary

This early-stage trial tests a new drug called PSW-1025, which delivers a radioactive particle (astatine-211) directly to prostate cancer cells. The goal is to see if this targeted approach is safe and tolerable for men with castration-resistant prostate cancer, a form that no longer responds to standard hormone therapy. The study will also help determine the right dose for future research.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: a targeted alpha therapy drug called PSW-1025, which delivers astatine-211 to prostate cancer cells
What this could lead to: If successful, this could lead to a more precise treatment for advanced prostate cancer that is resistant to standard hormone therapy.
What could go wrong: This is an early phase 1 trial with only 15 participants, so safety and effectiveness are not yet known. There may be unforeseen side effects from the radioactive component.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CASTRATION-RESISTANT PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

castration-resistant prostate carcinoma prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE CANCER

Contacts and locations

Locations

Osaka University Hospital

Suita, Osaka, 565-0871, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.